[go: up one dir, main page]

Witztum et al., 1998 - Google Patents

Oxidized phospholipids and isoprostanes in atherosclerosis

Witztum et al., 1998

Document ID
701390420747077344
Author
Witztum J
Berliner J
Publication year
Publication venue
Current opinion in lipidology

External Links

Snippet

Lipid oxidation has been shown to be a prominent feature of atherosclerosis. The presence of isoprostanes and other lipid oxidation products has been clearly demonstrated in lesions. Furthermore, antibodies to oxidized phopholipids have been identified in animal and human …
Continue reading at journals.lww.com (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/88—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving prostaglandins or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders

Similar Documents

Publication Publication Date Title
Witztum et al. Oxidized phospholipids and isoprostanes in atherosclerosis
Hurt-Camejo et al. Localization of nonpancreatic secretory phospholipase A2 in normal and atherosclerotic arteries: activity of the isolated enzyme on low-density lipoproteins
Cyrus et al. Disruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in apo E–deficient mice
Lee et al. All apoB-containing lipoproteins induce monocyte chemotaxis and adhesion when minimally modified: modulation of lipoprotein bioactivity by platelet-activating factor acetylhydrolase
O’Donnell et al. Enzymatically oxidized phospholipids assume center stage as essential regulators of innate immunity and cell death
Tsimikas et al. Oxidative modification of lipoproteins: mechanisms, role in inflammation and potential clinical applications in cardiovascular disease
Cathcart et al. Lipoxygenases and atherosclerosis: protection versus pathogenesis
Sutherland et al. Reduced postprandial serum paraoxonase activity after a meal rich in used cooking fat
Wang et al. Hyperhomocysteinemia accelerates atherosclerosis in cystathionine β-synthase and apolipoprotein E double knock-out mice with and without dietary perturbation
James et al. Smoking is associated with reduced serum paraoxonase activity and concentration in patients with coronary artery disease
Yu et al. Postprandial lipoproteins and atherosclerosis
Schissel et al. Secretory sphingomyelinase, a product of the acid sphingomyelinase gene, can hydrolyze atherogenic lipoproteins at neutral pH: implications for atherosclerotic lesion development
Shih et al. Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis
Subbanagounder et al. Determinants of bioactivity of oxidized phospholipids: specific oxidized fatty acyl groups at the sn-2 position
Webb et al. Macrophage-Expressed Group IIA Secretory Phospholipase A2 Increases Atherosclerotic Lesion Formation in LDL Receptor–Deficient Mice
Chung et al. Lipolytic surface remnants of triglyceride-rich lipoproteins are cytotoxic to macrophages but not in the presence of high density lipoprotein. A possible mechanism of atherogenesis?
Ziouzenkova et al. Dual roles for lipolysis and oxidation in peroxisome proliferation-activator receptor responses to electronegative low density lipoprotein
Pantazi et al. Oxidized phospholipids and lipoprotein‐associated phospholipase A2 (Lp‐PLA2) in atherosclerotic cardiovascular disease: An update
Vikramadithyan et al. Atherosclerosis in perlecan heterozygous mice
Doi et al. Membrane active lipids in remnant lipoproteins cause impairment of endothelium-dependent vasorelaxation
Goldberg et al. Responses to eating: lipoproteins, lipolytic products and atherosclerosis
CA2404000C (en) A functional assay of high-density lipoprotein
Jong et al. Both lipolysis and hepatic uptake of VLDL are impaired in transgenic mice coexpressing human apolipoprotein E* 3Leiden and human apolipoprotein C1
Zabalawi et al. Inflammation and skin cholesterol in LDLr−/−, apoA-I−/− mice: link between cholesterol homeostasis and self-tolerance?
Milosavljevic et al. VLDL-induced triglyceride accumulation in human macrophages is mediated by modulation of LPL lipolytic activity in the absence of change in LPL mass